Genmab A/S (WBO:GMAB)
€ 245 -1.8 (-0.73%) Market Cap: 15.71 Bil Enterprise Value: 11.88 Bil PE Ratio: 22.03 PB Ratio: 3.66 GF Score: 90/100

Q1 2021 Genmab A/S Earnings Call Transcript

May 05, 2021 / 04:00PM GMT
Release Date Price: €300.2 (+0.67%)
Operator

So hello, and welcome to the Genmab Conference Call to discuss the company's financial results for the period ended March 31, 2021. With me today to present these results is our CFO, Anthony Pagano.

Let's move to Slide 2. As already said, we will be making forward-looking statements. So please keep that in mind as we go through this call. Let's move to Slide 3. Genmab has an innovation-based culture and collaborations and partnerships have always been part of our DNA. During today's presentation, we will reference some of the products being developed under these strategic collaborations, and this slide acknowledges those relationships.

Let's move to Slide 4. Through our 22-year history, we've had a laser-sharp focus on harnessing the power of human antibodies to develop differentiated cancer therapeutics. This slide provides a review of what is behind that focus. Our core purpose, which guides our work, our extremely successful strategy and our ambitious vision for the company. Genmab's evolution into a fully integrated biotechnology power house continued with the events of the first

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot